Antengene Executives Boost Stakes in Vote of Confidence on Long-Term Growth

Antengene Corporation Limited ( (HK:6996) ) just unveiled an update.

Antengene Corporation Limited reported that its founder, chairman and CEO, Dr. Jay Mei, increased his stake in the company by purchasing 200,000 shares on the open market, lifting his interest to about 27.16% of issued shares. Executive director and CFO Donald Andrew Lung also acquired 502,500 shares, taking his holding to roughly 0.66%, while corporate vice president and board secretary Yang Cao bought additional shares for HK$1.042 million.

In total, the three senior executives invested HK$3.853 million, signaling strong confidence in Antengene’s long-term value, R&D capabilities and growth prospects. The company emphasized that the transactions complied with Hong Kong listing rules and that its public float remains sufficient, suggesting stable regulatory standing while reinforcing management’s commitment to the group’s strategic development and innovation pipeline.

The most recent analyst rating on (HK:6996) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

More about Antengene Corporation Limited

Antengene Corporation Limited is a Hong Kong-listed biopharmaceutical company focused on innovative oncology therapies. The group specializes in the research, development and commercialization of cancer drugs, aiming to advance a pipeline of targeted treatments to address unmet medical needs in global markets.

Average Trading Volume: 3,499,397

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.49B

For detailed information about 6996 stock, go to TipRanks’ Stock Analysis page.